<DOC>
	<DOCNO>NCT02197520</DOCNO>
	<brief_summary>This study look insulin sensitivity ( body respond insulin ) effect meal type 2 diabetic compare insulin peglispro insulin glargine . The study two treatment period , last four week . One drug ( insulin peglispro insulin glargine ) administer period . Participants receive drug study . Participants may remain stable dose metformin , prescribe personal physician .</brief_summary>
	<brief_title>A Study To Compare Effects Insulin Peglispro Glargine Insulin Sensitivity Meal Time Insulin Requirements Type 2 Diabetics</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Stable glycated hemoglobin ( HbA1c ) less ( &lt; ) 10.0 percent ( % ) Stable dose either 0.2 1.5 unit per kilogram per day ( U/kg/day ) basal insulin total daily insulin dose l &lt; 2.0 unit per kilogram ( U/kg ) Cpeptide &lt; 0.3 nanomole per liter ( nmol/L ) Stable body last 2 month Corrected QT interval ( QTc ) prolongation great ( &gt; ) 500 millisecond ( m ) abnormality 12 lead Abnormal blood pressure A history presence cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine ( apart Type 1 Diabetes Mellitus ( T1DM ) ) , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Currently treat oral antidiabetic drug ( OADs ) ( exclude metformin dipeptidyl peptidase4 ( DPP4 ) inhibitor ) , glucagonlike peptide1 ( GLP1 ) agonists intend use overthe counter prescription medication , herbal medication , nutritional supplement affect PG insulin sensitivity , impact hypoglycemic awareness promote weight loss within 4 week prior randomization Fasting triglyceride ( TGs ) &gt; 400 milligram per deciliter ( mg/dL ) ( 4.52 millimoles per liter ( mmol/L ) ) Have use systemic inhaled corticosteroids/glucocorticoid therapy ( exclude topical , intraarticular , intraocular preparation ) within 4 week prior randomization Currently receive insulin pump insulin degludec Poorly control diabetes know poor awareness hypoglycemia History gastroparesis gastrointestinal malabsorption Require treatment drug insulin treat diabetes Previous history proliferative retinopathy Excessive consumer xanthine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>